Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data

Lin Chang, William D. Chey, Lucinda Harris, Kevin Olden, Christina Surawicz, Philip Schoenfeld

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

BACKGROUND: Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies. This systematic review calculated the incidence of these adverse events in alosetron-using patients in clinical trials and post-marketing surveillance. METHODS: A panel of experts in epidemiology and functional bowel disorders reviewed clinical trial report forms and FDA MedWatch forms of each reported case of ischemic colitis or serious complications of constipation. Experts were blinded about whether patients used alosetron or placebo. Using pre-specified criteria, experts rated the likelihood of an accurate diagnosis and an association between medication use and adverse events. Cases that were not consistent with the reported diagnosis or not possibly associated with medication use were eliminated from calculation of incidence rates of adverse events. RESULTS: Pooled data from clinical trials indicate an increased rate of ischemic colitis among alosetron-using patients compared to placebo-using patients (0.15%vs 0.0%, respectively, p= 0.03), but there was no significant difference in the rate of serious complications of constipation. All (19/19) alosetron-using patients with ischemic colitis had reversible colitis without long-term sequelae. Based on post-marketing surveillance data, the post-adjudication rate of ischemic colitis is 1.1 per 1,000 patient-years of alosetron use and the rate of serious complications of constipation is 0.66 per 1,000 patient-years of alosetron use. CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely associated with long-term sequelae or serious morbidity.

Original languageEnglish (US)
Pages (from-to)1069-1079
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume101
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Ischemic Colitis
Constipation
Marketing
Clinical Trials
Incidence
Placebos
Colitis
alosetron
Diarrhea
Epidemiology
Morbidity

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron : Systematic review of clinical trials and post-marketing surveillance data. / Chang, Lin; Chey, William D.; Harris, Lucinda; Olden, Kevin; Surawicz, Christina; Schoenfeld, Philip.

In: American Journal of Gastroenterology, Vol. 101, No. 5, 05.2006, p. 1069-1079.

Research output: Contribution to journalArticle

Chang, Lin ; Chey, William D. ; Harris, Lucinda ; Olden, Kevin ; Surawicz, Christina ; Schoenfeld, Philip. / Incidence of ischemic colitis and serious complications of constipation among patients using alosetron : Systematic review of clinical trials and post-marketing surveillance data. In: American Journal of Gastroenterology. 2006 ; Vol. 101, No. 5. pp. 1069-1079.
@article{28b90244b4264fdfa19dcee457c94e2b,
title = "Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data",
abstract = "BACKGROUND: Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies. This systematic review calculated the incidence of these adverse events in alosetron-using patients in clinical trials and post-marketing surveillance. METHODS: A panel of experts in epidemiology and functional bowel disorders reviewed clinical trial report forms and FDA MedWatch forms of each reported case of ischemic colitis or serious complications of constipation. Experts were blinded about whether patients used alosetron or placebo. Using pre-specified criteria, experts rated the likelihood of an accurate diagnosis and an association between medication use and adverse events. Cases that were not consistent with the reported diagnosis or not possibly associated with medication use were eliminated from calculation of incidence rates of adverse events. RESULTS: Pooled data from clinical trials indicate an increased rate of ischemic colitis among alosetron-using patients compared to placebo-using patients (0.15{\%}vs 0.0{\%}, respectively, p= 0.03), but there was no significant difference in the rate of serious complications of constipation. All (19/19) alosetron-using patients with ischemic colitis had reversible colitis without long-term sequelae. Based on post-marketing surveillance data, the post-adjudication rate of ischemic colitis is 1.1 per 1,000 patient-years of alosetron use and the rate of serious complications of constipation is 0.66 per 1,000 patient-years of alosetron use. CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely associated with long-term sequelae or serious morbidity.",
author = "Lin Chang and Chey, {William D.} and Lucinda Harris and Kevin Olden and Christina Surawicz and Philip Schoenfeld",
year = "2006",
month = "5",
doi = "10.1111/j.1572-0241.2006.00459.x",
language = "English (US)",
volume = "101",
pages = "1069--1079",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Incidence of ischemic colitis and serious complications of constipation among patients using alosetron

T2 - Systematic review of clinical trials and post-marketing surveillance data

AU - Chang, Lin

AU - Chey, William D.

AU - Harris, Lucinda

AU - Olden, Kevin

AU - Surawicz, Christina

AU - Schoenfeld, Philip

PY - 2006/5

Y1 - 2006/5

N2 - BACKGROUND: Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies. This systematic review calculated the incidence of these adverse events in alosetron-using patients in clinical trials and post-marketing surveillance. METHODS: A panel of experts in epidemiology and functional bowel disorders reviewed clinical trial report forms and FDA MedWatch forms of each reported case of ischemic colitis or serious complications of constipation. Experts were blinded about whether patients used alosetron or placebo. Using pre-specified criteria, experts rated the likelihood of an accurate diagnosis and an association between medication use and adverse events. Cases that were not consistent with the reported diagnosis or not possibly associated with medication use were eliminated from calculation of incidence rates of adverse events. RESULTS: Pooled data from clinical trials indicate an increased rate of ischemic colitis among alosetron-using patients compared to placebo-using patients (0.15%vs 0.0%, respectively, p= 0.03), but there was no significant difference in the rate of serious complications of constipation. All (19/19) alosetron-using patients with ischemic colitis had reversible colitis without long-term sequelae. Based on post-marketing surveillance data, the post-adjudication rate of ischemic colitis is 1.1 per 1,000 patient-years of alosetron use and the rate of serious complications of constipation is 0.66 per 1,000 patient-years of alosetron use. CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely associated with long-term sequelae or serious morbidity.

AB - BACKGROUND: Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies. This systematic review calculated the incidence of these adverse events in alosetron-using patients in clinical trials and post-marketing surveillance. METHODS: A panel of experts in epidemiology and functional bowel disorders reviewed clinical trial report forms and FDA MedWatch forms of each reported case of ischemic colitis or serious complications of constipation. Experts were blinded about whether patients used alosetron or placebo. Using pre-specified criteria, experts rated the likelihood of an accurate diagnosis and an association between medication use and adverse events. Cases that were not consistent with the reported diagnosis or not possibly associated with medication use were eliminated from calculation of incidence rates of adverse events. RESULTS: Pooled data from clinical trials indicate an increased rate of ischemic colitis among alosetron-using patients compared to placebo-using patients (0.15%vs 0.0%, respectively, p= 0.03), but there was no significant difference in the rate of serious complications of constipation. All (19/19) alosetron-using patients with ischemic colitis had reversible colitis without long-term sequelae. Based on post-marketing surveillance data, the post-adjudication rate of ischemic colitis is 1.1 per 1,000 patient-years of alosetron use and the rate of serious complications of constipation is 0.66 per 1,000 patient-years of alosetron use. CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely associated with long-term sequelae or serious morbidity.

UR - http://www.scopus.com/inward/record.url?scp=33646441324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646441324&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.00459.x

DO - 10.1111/j.1572-0241.2006.00459.x

M3 - Article

C2 - 16606352

AN - SCOPUS:33646441324

VL - 101

SP - 1069

EP - 1079

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -